World’s first acoustic cluster therapy trial could enhance chemotherapy targeting

The first patient has been treated with acoustic cluster therapy, an innovative new technology that could improve targeting of chemotherapy and reduce doses necessary for a response to the treatment. The Phase I/II clinical trial is being conducted by multidisciplinary teams at The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation (both London, UK), with the intent to provide early data on the efficacy and safety of the treatment. Acoustic cluster therapy (ACT) was invented by Phoenix Solutions (Oslo, Norway) and further developed at The ICR and the Norwegian University of Science and Technology (Trondheim, Norway). The...